CTOs on the Move

Nohla Therapeutics

www.nohlatherapeutics.com

 
Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy targeting hematopoietic recovery and chemotherapy induced neutropenia, and is being extended to treat a range of other medical indications. This and other products in the pipeline are based on a unique umbilical cord blood expansion platform developed at the Fred Hutchinson Cancer Research Center
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Nohla Therapeutics raised $20M on 12/03/2015
Nohla Therapeutics raised $43.5M on 11/30/2016
Nohla Therapeutics raised $45M on 05/15/2018
Nohla Therapeutics raised $49M on 07/12/2018
Nohla Therapeutics raised $11M on 07/12/2018

Similar Companies

Access Biologicals

Access Biologicals is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Center for Breakthrough Medicines

The Center for Breakthrough Medicines is the Worlds Largest and Most Advanced Single Solution Cell and Gene Therapy Contract Development and Manufacturing Organization. Period.

Syantra

With a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, more than half of women have a reduced opportunity for an early, life-saving diagnosis. That`s why we`re developing Syantra DX: a blood test to detect breast cancer. It`s a revolutionary, rapid, economical approach to breast cancer screening that`s accurate regardless of the test recipient`s family history, age or tissue density.

DiaCarta

DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world.

Metavention

Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes. Metabolic Neuromodulation Therapy (MNT) is a simple cardiovascular procedure intended to modulate sympathetic nervous system activity in patients with Type 2 diabetes for the purpose of lowering blood glucose levels. MNT was developed based on published scientific data and extensive animal studies suggesting a link between elevated sympathetic nerve activity in the metabolic system and increased levels of blood glucose. MNT is currently being studied in human clinical trials and represents a potentially important new treatment option for patients with Type 2 Diabetes.